Active, not recruitingPhase 1NCT03361436

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Studying Liposarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
OHSU Knight Cancer Institute
Principal Investigator
Lara E Davis
OHSU Knight Cancer Institute
Intervention
Eribulin Mesylate(drug)
Enrollment
15 enrolled
Eligibility
12 years · All sexes
Timeline
20182033

Study locations (1)

Collaborators

Eisai Inc. · Oregon Health and Science University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03361436 on ClinicalTrials.gov

Other trials for Liposarcoma

Additional recruiting or active studies for the same condition.

See all trials for Liposarcoma

← Back to all trials